NeuroPace, Inc. (NPCE)
Nasdaq · Healthcare · Medical Devices
$13.22+4.09%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $454M
- 52-week range
- $9.22 – $19.60
- 52-week change
- +19.25%
- EPS (trailing)
- −$0.57
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $100.0M (+25.13%)
- Net income
- −$21.5M
- Operating margin
- −16.3%
- Diluted EPS
- −$0.66
- Free cash flow
- −$11.3M
From the company’s annual report on SEC EDGAR.
About NeuroPace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Headquarters: Mountain View, United States · 220 employees · neuropace.com